Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Neurociencia
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Mexicana de Neurociencia >Año 2006, No. 3


Aguilar FL, Morgade FRM, Rodríguez VRF, Alvarez AA
Deterioro cognitivo en la epilepsia
Rev Mex Neuroci 2006; 7 (3)

Idioma: Español
Referencias bibliográficas: 90
Paginas: 218-224
Archivo PDF: 83.00 Kb.

[Texto completo - PDF]

FRAGMENTO

Introducción: La infancia es la etapa donde alrededor de ¾ partes de los enfermos epilépticos empiezan a manifestar sus ataques, la mayoría de éstos llevan un estilo de vida normal. La prevalencia de los trastornos conductuales entre los niños epilépticos es 4.7 veces mayor que en los niños sanos. Factores orgánicos: La epilepsia produce deterioro cognitivo, el cual se incrementa si la misma se asocia a daño cerebral. En los sujetos epilépticos con lesión, el deterioro cognitivo está relacionado con la función fisiológica del sitio anatómico afectado. Factores relacionados con la enfermedad: Entre estos factores destacan por su importancia la etiología de la epilepsia, la edad de inicio de las crisis, la duración de la enfermedad, el tipo y la frecuencia de las crisis, así como las descargas epileptiformes subclínicas. La decisión de iniciar el tratamiento antiepiléptico debe estar basada en una relación riesgo-beneficio. Conclusiones: Los efectos en el control de la crisis pueden mejorar la cognición y la conducta con el uso de nuevos fármacos antiepilépticos. Finalmente, también es importante el uso de la monoterapia y tener en cuenta los problemas que la politerapia puede producir aumentando la probabilidad de aparición de efectos adversos y de interacciones medicamentosas.


Palabras clave: enfermo epiléptico, deterioro cognitivo, fármacos antiepilépticos.


REFERENCIAS

  1. Trimble M. Cognitive problems of patients with seizure disorders. New issues in neurosciences basic and clinical approaches. Neuropsychological aspects in epilepsy 1992; 4: 17-24.

  2. Holmes GL. Do seizures cause brain damage? Epilepsy 1991; 32(Suppl. 5): S14-28.

  3. Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 4(Suppl. 2): S25-38.

  4. Austin JK, Dunn DW. Progressive behavioral changes in children with epilepsy. Prog Brain Res 2002; 135: 419-27.

  5. Lassonde M, Sauerwein HC, Jambeque I, Smith ML, Helmstaedter C. Neuropsychology of childhood epilepsy: pre-and postsurgical assessment. Epileptic Disord 2000; 2: 3-13.

  6. Miyamoto T, Katayama J, Kohsaka M, Koyama T. Disturbance of semantic processing in temporal lobe epilepsy demonstrated with scalp-ERPs. Seizure 2000; 9: 572-9.

  7. Noeker M, Haverkamp-Krois A, Haverkamp F. Development of mental health dysfunction in childhood epilepsy. Brain & Development 2005; 1: 5-16.

  8. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001; 357: 216-22.

  9. Artigas J. Manifestaciones psicológicas de la epilepsia en la infancia. Rev Neurol 1999; 28(Supl. 2): S135-41.

  10. Deonna T. Cognitive and behavioral disturbance as epileptic manifestations in children: an overview. Semin-Pediatr-Neurol 1995; 2: 254-60.

  11. Maestu F, Martin P, Sola RG, Ortiz T. Neuropsychology and cognitive deterioration in epilepsy. Rev Neurol 1999; 28: 793-8.

  12. Mataro SM, Junque PC. Memory and epilepsy. Rev Neurol 1997; 25: 1241-5.

  13. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44(Suppl. 4): 21-9.

  14. Drane DL, Meador KJ. Epilepsy, anticonvulsant drugs and cognition. In: Brodie MJ, Treiman DM (eds.). Modern management of epilepsy. London: Bailliere-Tindall; 1996, p. 877-85.

  15. Hermann BP, Seidenberg M, Schoenfeld J, Davies K. Neuropsychological characteristics of the syndrome of mesial temporal lobe epilepsy. Arch neurol 1997; 54: 369-76.

  16. Klein B, Levin BE, Duchowny MS, Llabre MM. Cognitive outcome of children with epilepsy and malformations of cortical development. Neurology 2000; 55: 230-5.

  17. Hauser WA. Incidence and prevalence. Epilepsy: The comprehensive CD-ROM. Baltimore: Lippincott Williams & Wilkins; 1999.

  18. Battaglia D, Rando T, Deodato F, Bruccini G, Baglio G, Frisone MF, et al. Epileptic disorders with onset in the first year of life: neurological and cognitive outcome. Eur J Paediat Neurol 1999; 3: 95-103.

  19. Aldenkamp AP, et al. Acute cognitive effects of nonconvulsive difficult-to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol 2001; 16: 119-23.

  20. Tromp SC, Weber JW, Aldenkamp AP, Arends J, Vander Linden I, Diepman L. Relative influence of epileptic seizures and of epilepsy syndrome on cognitive function. J Child Neurol 2003; 18: 407-12.

  21. Aldenkamp A, Aredens J. The relative influence of epileptic EEG discharge, short nonconvulsive seizures, and type of epilepsy on cognitive function. Epilepsia 2004; 45: 54.

  22. Oxbury S. Neuropsychological evaluation-children. Epilepsy: The comprehensive CD-ROM. Baltimore: Lippincott: Williams & Wilkins; 1999.

  23. Echenne B, Chemical R, Roubertier A, Rivier F. Are idiopathic generalized epilepsies of childhood really benign? Epileptic Disord 2001; 3: 67-72.

  24. Jambeque I, Dellatolas G. Dulac O, Ponsot G, Signore JL. Verbal and visual memory impairment in children with epilepsy. Neuropsychologia 1993; 31: 1321-37.

  25. Deonna T. Rolandic epilepsy: neuropsychology of the active epilepsy phase. Epileptic Disord 2000; 2: 59-61.

  26. Wirrell EC. Being epilepsy of childhood with centrotemporal spikes. Epilepsia 1998; 39: 32-41.

  27. Holmes GL. Benign focal epilepsies of childhood. Epilepsia 1993; 34: 49-61.

  28. Hirsch E, De Saint-Martin A, Arzimanoglou A. New insights into the clinical management of partial epilepsies. Epilepsia 2000; 41: 13-7.

  29. Carlsson G, Igelbrink-Schulze N, Neubauer BA, Stephani. Neuropsychological long-term outcome of rolandic EEG traits. Epileptic Disord 2000; 2: 63-6.

  30. Doose H, Neubauer BA, Petersen B. The concept of hereditary impairment of brain maturation. Epileptic Disord 2000; 2: 45-9.

  31. Gordon N. Cognitive functions and epileptic activity. Seizure 2000; 9: 184-8.

  32. Papazian O, Alfonso I, García-Galarreta V. Efecto de las descargas epileptiformes interictales sobre las funciones cognitivas en niños con epilepsia idiopática. Rev Neurol 2003; 36: 282-4.

  33. Prevey ML, Delaney RC, Cramer JA, Mattson RH. Complex partial and secondarily generalized seizure patients: cognitive functioning prior to treatment with antiepileptic medication. VA Epilepsy Cooperative Study 264 Group. Epilepsy Res 1998; 30: 1-9.

  34. Mandelbaum DE, Burack GD. The effect of seizure type and medication on cognitive and behavioral functioning in children with idiopathic epilepsy. Dev Med Child Neurol 1997; 39: 731-5.

  35. Gibbs FE, Lennox WG, Gibbs EL. The electroencephalogram in diagnosis and in localization of epileptic seizures. Arch Neurol Psychiatry 1936; 36: 1225-35.

  36. Schwab RS. A method of measuring consciousness in attack of petit mal epilepsy. Arch Neurol Psychiatry 1939; 41: 215-7.

  37. Aarts JH, Binnie CD, Smit AM, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984; 107: 293-308.

  38. Metz-Lutz MN, de Saint-Martin A. Pathophysiological accounts of language impairments in Landau-Kleffner syndrome. Epileptic Disord 2001; 3: 163-4.

  39. Matsuoka H, Takahashi T, Sasaki M, Matsumoto K, Yoshida S, Numachi Y, et al. Neuropsychological EEG activation in patients with epilepsy. Brain 2000; 123: 318-30.

  40. Matsuoka H. Neuropsychology of epilepsy. Epilepsia 2001; 42: 42-6.

  41. Wolf P, Inoue Y. Complex reflex epilepsies: reading epilepsy and praxis induction seizures. In: Roger J, et al. (eds.). Epileptic syndrome in infancy, childhood and adolescence. London: John Libbey; 2002, p. 315-25.

  42. Inoue Y, Seino M, Tanaka M, Kubota H, Yamakaku K, Yagi K. Epilepsy with praxis-induced seizures. In: Wolf P, (ed.). Epileptic seizures and syndromes. London: John Libbey; 1994, p. 81-91.

  43. Binnie CD, Kastelejein Nolst-Trenité DGA, Smit AM, Wilkins AJ. Interactions of epileptiform EEG discharges and cognition. Epilepsy Res 1987; 1: 239-45.

  44. Binnie CD. Transitory cognitive impairment during subclinical EEG discharges. Advances in Epileptology 1989; 17: 407-9.

  45. Kasteleijin-Nolst Trenite DG. Transient cognitive impairment during subclinical epileptiform electroencephalographic discharges. Semin Pediatr Neurol 1995; 2: 246-53.

  46. Binnie CD. Cognitive impairment during epileptiform discharges: is it ever justificable to treat the EEG? Lancet Neurol 2003; 2: 725-30.

  47. Binnie CD, Channon S, Marston D. Learning disabilities in epilepsy: neurophysiological aspects. Epilepsia 1990; 31: 2-3.

  48. Binnie CD. Significance and management of transitory cognitive impairment due to subclinical EEG discharge in children. Brain Dev 1993; 15: 389.

  49. Ortinski P, Meador KJ. Cognitive side effects of epileptic drugs. Epilepsy Behav 2004; 5(Suppl. 1): S60-5.

  50. Reséndiz-Aparicio JC, Rodríguez ER, Bernal JC, Moreno HC, Pérez EB, Morales SG, et al. Estudio abierto aleatorio y comparativo de la monoterapia con topiramato frente a carbamazepina en el tratamiento de pacientes pediátricos con epilepsia de reciente diagnóstico. Rev Neurol 2004; 39: 201-4.

  51. Drane DL, Meador KJ. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 2002; 3: 49-53.

  52. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36(Suppl. 2): S46-65.

  53. Freeman JM, Pedley TA. Indications for treatment. In: Engel J, Pedley TA (eds.). Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  54. Dulac O, Leppik EI. Initiating and discontinuing treatment. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  55. Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997; 26: 423-32.

  56. Malagón-Valdez J. Efectos cognitivos de los fármacos antiepilépticos. Rev Neurol 2003; 36: 288-92.

  57. Eadie MJ. Phenobarbital and other barbiturates. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  58. Kalviainen R, Aikia M, Riekkinenn PJ. Cognitive adverse effects of antiepileptic drugs: incidence, mechanisms and therapeutic implications. CNS Drugs 1996; 5: 358-68.

  59. Browne TR. Phenytoin and other hydantoins. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  60. Bruni J. Phenytoin: toxicity. In: Levy RH, Mattson RH, Meldrum BS (Ed.). Antiepileptic drugs. New York: Rave Press; 1995, p. 345-58.

  61. Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in health adults. Epilepsia 1993; 34: 153-7.

  62. Verma NP, Yusko MJ, Greiffenstein MF. Carbamazepine offers no psychotropic advantage over phenytoin in adult epileptic subjects. Seizure 1993; 2: 53-6.

  63. Mattson RH. Carbamazepine. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  64. Meador KJ, Loring DW, Allen ME. Comparative cognitive effects of carbamazepine and phenytoin in health adults. Neurology 1991; 41: 1537-40.

  65. Meador KJ, Loring DW, Hun K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsant. Neurology 1990; 40: 391-4.

  66. Aldenkamp AP, Alpherts WJ, Blennow G, Elmquist D, Heijbel J, Nilsson HL, et al. Withdrawal of antiepileptic medication: effects on cognitive function in children. Results of the multicenter Holmfrid study. Neurology 1993; 43: 41-51.

  67. Guillham RA, Read CL, Mackee PJW, Larkin JG, Brodie MJ. Cognitive function in adult epileptic patients on long-term sodium valproate. J Epilepsy 1991; 4: 205-10.

  68. Rowan AJ. Valproate. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  69. Schmidt D. Adverse effects of valproate. Epilepsia 1984; 25(Suppl. 1): S544-9.

  70. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-90.

  71. Ko DY, Rho JM, DeGiorgio CM, Sato S. Benzodiazepines. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  72. Besag FMC. Lamotrigine in the management of subtle seizures. Rev Contemp Pharmacother 1994; 5: 123-31.

  73. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991; 32(Suppl. 2): S17-21.

  74. Uldall P, Hansen FJ, Tonnby B. Lamotrigine. In: Rett syndrome. Neuropediatrics 1993; 24: 339-40.

  75. Uvebrant P, Bauzlene R. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994; 25: 284-9.

  76. Binnie CD, Beintema DJ, Debets RMC, et al. Seven-day administration of lamotrigine in epilepsy: add-on trial. Epilepsy Res 1987; 1: 202-8.

  77. Jawad S, Oxley J, Yuen WC, Richens A. The effects of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. Br J Clin Pharmacol 1986; 22: 191-3.

  78. Binnie CD. Lamotrigine. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  79. French JA, Ben-Menachen E. Vigabatrin. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  80. Appelton R. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology 1993; 43(Suppl. 5): S21-3.

  81. Diamond KR, Pande AC, LaMoreaux L, Pierce MW. Effect of gabapentin on mood and well being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407-17.

  82. Martin R, Kuzniecky R, Ho S. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321-7.

  83. Gram L. Oxcarbazepine. Epilepsy: The comprehensive CD-ROM. Lippincott: Williams & Wilkins; 1999.

  84. Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ. Cognitive effects of oxcarbamazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199-203.

  85. Sabers A. Effect of monotherapeutic antiepileptic drugs on cognitive functions in patients with epilepsy. Epilepsia 1993; 34(Suppl.): 11.

  86. Curran HV, Java V. Memory of psychomotor effects of oxcarbazepine in healthy human volunteers. Eur F Clin Pharmacol 1993; 44: 529-33.

  87. Sveinbjornsdottir S, Snader JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3: 29-35.

  88. Kalviainen R, Aikia M, Mervaala E, Saukkonen AM, Pikanen A, Riekkinen Sr PJ. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996; 25: 291-7.

  89. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48: 1031-5.

  90. Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33-42.



>Revistas >Revista Mexicana de Neurociencia >Año2006, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 
       
Derechos Resevados 2007